文献速递针灸推拿中医康复

血清趋化因子CXCL1介导手针刺激ST36的抗伤害感受效应

Chemokine CXCL1 in serum mediates the antinociceptive effect of manual acupuncture at ST36.
PubMed 文献 · Acupunct Med · 2021-03-11

该研究在大鼠完全弗氏佐剂(CFA)炎症痛模型中观察手针(MA)刺激ST36的镇痛效应及血清CXCL1的作用。结果显示MA可提高热痛阈并上调血清CXCL1,重组CXCL1具镇痛效应,抗CXCL1抗体中和血清CXCL1可削弱MA镇痛,且MA与CXCL1的镇痛均可被纳洛酮逆转。提示血清CXCL1参与MA抗伤害感受的外周机制,可能经外周阿片通路介导。

要点

  • MA刺激ST36可提高CFA炎症痛大鼠的热痛阈并上调血清CXCL1。
  • 血清CXCL1中和可削弱MA镇痛,提示其参与MA外周镇痛机制。
  • MA与重组CXCL1的镇痛效应均可被局部纳洛酮逆转。

核心结论

  • 手针刺激ST36对CFA诱导的炎症痛具有镇痛效应,血清CXCL1上调参与该抗伤害感受过程。
  • MA或重组CXCL1的镇痛效应可能经外周阿片通路介导,尚需进一步研究。

研究设计与样本

  • 大鼠右侧后足底注射CFA建立炎症痛模型,每日MA刺激ST36,第1天至第7天。
  • ELISA测定首次和末次MA后血清CXCL1浓度;尾静脉注射重组CXCL1(5或10 μg)或抗CXCL1抗体(6.4或16 μg,MA前30 min)并测痛阈。
  • 末次MA或末次重组CXCL1注射前5 min于炎性足底注射纳洛酮(500 μg,0.1 mL)。

主要发现

  • MA显著提高CFA大鼠热痛阈(PWL)并上调血清CXCL1表达。
  • 不针刺时,重复尾静脉注射重组CXCL1对CFA炎症痛显示镇痛效应。
  • 抗CXCL1抗体中和血清CXCL1以时间依赖方式降低MA抗伤害感受;首次MA前单次注射抗CXCL1抗体不影响MA镇痛。
  • MA与重组CXCL1的镇痛效应均可被足底注射纳洛酮逆转。

关键数值与推荐

  • 重组CXCL1尾静脉注射剂量为5或10 μg,每日1次,第1天至第7天。
  • 抗CXCL1抗体尾静脉注射剂量为6.4或16 μg,于MA前30 min给药。
  • 纳洛酮剂量为500 μg(0.1 mL),于末次MA或末次重组CXCL1注射前5 min足底注射。

临床怎么用

  • 动物实验提示ST36手针镇痛可能伴随血清CXCL1升高,CXCL1或为外周镇痛机制的相关分子。
  • 抗CXCL1中和可削弱MA镇痛,提示临床联合免疫调节药物时需关注对针刺镇痛的潜在影响。
  • 纳洛酮可逆转MA镇痛,提示阿片通路参与,临床使用阿片拮抗剂时需考虑针刺疗效。

局限性

  • 研究为CFA大鼠炎症痛模型,结论外推至临床人群需谨慎。
  • MA或重组CXCL1经外周阿片通路介导的镇痛机制尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inflammatory pain is the most common type of pain encountered clinically. The analgesic effect of acupuncture has been well-documented. OBJECTIVE: The aim of this study was to investigate the involvement of chemokine CXCL1 in the serum on manual acupuncture (MA)-induced antinociception. METHODS: Rats with inflammatory pain of the right hind paw were induced by intraplantar (i.pl.) administration of complete Freund's adjuvant (CFA). After wards, the CFA-injected rats were treated daily with MA at ST36 from Day 1 to Day 7, and thermal nociceptive thresholds (paw withdrawal latency; PWL) were analyzed. The concentration of CXCL1 in the serum of the rats was measured by enzyme-linked immunosorbent assay (ELISA) after the first and the last MA treatment. Subsequently, the rats were injected with two doses (5 or 10 μg) of recombinant CXCL1 through the tail vein daily from Day 1 to Day 7 or injected with two doses (6.4 or 16 μg) of anti-CXCL1 antibody using the same methods and course at 30 min before MA, and the PWLs were measured again. Finally, naloxone (500 μg, 0.1 mL) was administered by i.pl. injection into the inflamed paw 5 min before the last MA treatment or last injection of recombinant CXCL1. RESULTS: MA significantly increased the PWLs and upregulated the expression of serum CXCL1 in the CFA-injected rats. Without acupuncture, repeated tail vein injection of recombinant CXCL1 showed an analgesic effect on CFA-induced inflammatory pain. Conversely, the neutralization of serum CXCL1 by anti-CXCL1 antibody decreased MA-induced antinociception in a time-dependent manner. Anti-CXCL1 antibody injected just once before the first MA did not affect MA-induced antinociception. The analgesic effects of MA and recombinant CXCL1 were reversed by an i.pl. injection of naloxone. CONCLUSION: This study indicates MA at ST36 had an analgesic effect on inflammatory pain and found a novel function of CXCL1. Increased serum CXCL1 had an antinociceptive effect on inflammatory pain induced by CFA. CXCL1 in serum appeared to be a key molecule involved in the peripheral mechanism of MA-induced antinociception. The analgesic effect of MA or recombinant CXCL1 on inflammatory pain might be mediated through a peripheral opioid pathway, which needs further investigation.

来源:Acupunct Med,查看原文。版权归原作者所有。

引用

  1. Hong SH, Ding SS, Xu Y, et al. Chemokine CXCL1 in serum mediates the antinociceptive effect of manual acupuncture at ST36. Acupunct Med. 2021. PMID: 33706560. doi:10.1177/0964528421997435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。